https://www.selleckchem.com/products/pfi-3.html
To investigate the efficacy of aflibercept for the treatment of diabetic macular edema via a treat-and-extend regimen. This prospective, single-center, open-label, interventional study involved 30 patients with a best-corrected visual acuity (BCVA) ≤0.6 and a central retinal thickness (CRT) ≥300 μm. The enrolled eyes each received a monthly intravitreal aflibercept injection until the CRT decreased below 300 μm, upon which the administration interval was extended for 1 month until the CRT once again increased to ≥300 μm. Main outcome meas
Like
Comment
Share
